BTEN Begins Full-Scale Discussions on Pet Business Model with Medicloud and XOOX LAB

BTuen, an AI and big data specialized company (CEO Joo Hyun-jung, Park Jong-yul), is actively expanding its digital healthcare business.

BTuen recently announced that through a share acquisition, it is in active discussions with XOOX LAB Inc., the developer of the pet-exclusive app ‘XOOX’ which is expanding globally starting from the United States, and is working on a pet networking service (PNS) business model via the genetic analysis company Medicloud.

XOOX LAB recently launched a pet app. According to multiple foreign media reports, XOOX LAB, based on Medicloud’s top-tier DNA testing technology in Korea, has introduced diagnostic and predictive tests for pet diseases and conditions, and forensic technology for pet identification. They have released a urine diagnostic kit and app for pets that are difficult to diagnose early. Additionally, they plan to sequentially launch an MBTI analysis app reflecting pets’ behavioral development models.

Through this agreement, the company will analyze over 100 million DNA big data (users) collected via the pet-exclusive app. Furthermore, by utilizing AI-based eyelid and eye area pattern analysis, they plan to officially start a big data business using pet ID services and various applications and algorithms based on this.

The XOOX app, which is the first service to be provided, operates with pet accounts rather than human accounts and assigns IDs through biometric recognition. Notably, the world’s first biometric ID using eyelid and wrinkle patterns around the pet’s eyes compensates for the low accuracy of vein recognition and iris recognition. The app attracted attention upon its release on the 11th by revealing videos sending messages to Oprah Winfrey and Elon Musk.

A company representative stated, “To actively proceed with the pet healthcare service business, we made an investment in Medicloud and formed a strategic partnership with XOOX LAB. We acquired shares after receiving a fair valuation from an external evaluation agency for the Medicloud investment.”

They added, “Medicloud, with its differentiated predictive services based on NGS (Next Generation Sequencing) technology and expansion into various ICT (Information and Communication Technology) business fields, has selected Shinhan Investment Corp. as the lead underwriter for its IPO and is proceeding with the IPO process. Alongside the IPO, discussions are also underway for technology transfer related to the global genome platform.”